Takeover bid is being completed – Japanese company acquires Calliditas

Japanese company Asahi Kasei completes the bid for Calliditas Therapeutics after reaching over 90 percent of the shareholding. Callidita's board has now decided...

Glatt besked för Lundabolag – Europapatent på väg att beviljas

Synact Pharma kommer att beviljas europeiskt patent för den kliniska formuleringen av Resomelagon, enligt ett förhandsbesked till företaget.

Join the premier metrology and quality assurance event of the year

ZEISS QUALITY INNOVATION SUMMIT in Berlin, October 22-24, 2024.

Anna Törner: Yes, I Am Sick, But Not Weak

”People often say that someone who is ill only has one wish—to get better. But I think that is not true. Someone who is ill also longs to be understood, to be r...

Achieve Efficient, Fast Targeting of Your Sample

Step into the future of imaging technology with VersaXRM 730.

MSD discontinues two Keytruda trials

MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.

To build trust, one must be able to say “I don’t know” – whether human or AI

Will AI strengthen or break down trust? It depends on whether we can understand and accept its limitations, and our own, writes Sarah Lidé in a column.

Healthcare study: Alzheimer’s blood test shows high accuracy

A blood test for identifying Alzheimer’s has now been tested in the general healthcare setting. According to the researchers, the test was 90% accurate in making a diagnosis.

Mastering Urine Microscopy

On-demand Webinar: Microscopy in urinalysis.

Higher throughput in less time

Do you want to automate your quality processes, shorten inspection times and increase your throughput? Gain inspiration from the experience of the medical techn...

Johan Pehrson takes over the responsibility for research policy in Sweden

The Liberals' party leader Johan Pehrson takes over the assignment as Minister for Education. This was announced by Prime Minister Ulf Kristersson (M) on Tuesday last week.

Optimize Your Visibility

ZEISS presents our newest VersaXRM® 730 3D X-ray microscope.

The investor: “The major common diseases are hot again”

She has previously been voted Investor of the Year and will now be moderating The Future of Swedish & Danish Life Science congress. We check the temperature of ...

Thumbs down for lecanemab in the EU – “Very surprised”

The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), acc...

A small thing that can solve your problems

If you are in need of a compact valve. Look no further! We have the VOVK

Japanese pharma to buy US drugmaker for $2.4 bln

Japanese Ono Pharmaceutical buys the American cancer drug developer Deciphera Pharmaceuticals in one of the largest acquisitions in the industry so far this year.

The first drugs to slow down Alzheimer’s – but what does it mean for patients?

Science Sweden has spoken to Swedish researchers in Alzheimer’s who voice cautious hope but also see further challenges.

Drug development booms in Medicon Valley

When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on commission for pharmaceutical compani...

Amrop Malmö AB

Gothenburg, the city of life science – We are ‘Little Boston’

Western Sweden is investing in life science within everything from advanced therapeutic drugs to femtech. At the same time, stakeholders are looking to other in...

Compact and leak-tight powerhouse

Media-separated solenoid valve VYKA from Festo is virtually leak-free

SupraCube - In life Science

Superconductors must be permanently kept below their transition temperature for levitation. Because of the integrated cooler, applications with superconductors ...

VPN till Android skyddar din data och identitet

För att hålla din Android säker från intrång från hackare så kan du använda VPN, antivirusprogram och säkerhetskopiering. Läs mer här!

Thomas Eldered: ”Innovation is the key”

Thomas Eldered speaks in a web clip about the challenges facing the life science sector in the future and what he, as an investor, finds most interesting in new companies.